TY - JOUR
T1 - Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation
T2 - Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation
AU - Inamoto, Yoshihiro
AU - Petriček, Igor
AU - Burns, Linda
AU - Chhabra, Saurabh
AU - DeFilipp, Zachariah
AU - Hematti, Peiman
AU - Rovó, Alicia
AU - Schears, Raquel
AU - Shah, Ami
AU - Agrawal, Vaibhav
AU - Ahmed, Aisha
AU - Ahmed, Ibrahim
AU - Ali, Asim
AU - Aljurf, Mahmoud
AU - Alkhateeb, Hassan
AU - Beitinjaneh, Amer
AU - Bhatt, Neel
AU - Buchbinder, Dave
AU - Byrne, Michael
AU - Callander, Natalie
AU - Fahnehjelm, Kristina
AU - Farhadfar, Nosha
AU - Gale, Robert Peter
AU - Ganguly, Siddhartha
AU - Hashmi, Shahrukh
AU - Hildebrandt, Gerhard C.
AU - Horn, Erich
AU - Jakubowski, Ann
AU - Kamble, Rammurti T.
AU - Law, Jason
AU - Lee, Catherine
AU - Nathan, Sunita
AU - Penack, Olaf
AU - Pingali, Ravi
AU - Prasad, Pinki
AU - Pulanic, Drazen
AU - Rotz, Seth
AU - Shreenivas, Aditya
AU - Steinberg, Amir
AU - Tabbara, Khalid
AU - Tichelli, André
AU - Wirk, Baldeep
AU - Yared, Jean
AU - Basak, Grzegorz W.
AU - Battiwalla, Minoo
AU - Duarte, Rafael
AU - Savani, Bipin N.
AU - Flowers, Mary E.D.
AU - Shaw, Bronwen E.
AU - Valdés-Sanz, Nuria
N1 - Publisher Copyright:
© 2018 American Society for Blood and Marrow Transplantation
PY - 2019/5
Y1 - 2019/5
N2 - Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.
AB - Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.
KW - Complication
KW - Eye
KW - Hematopoietic cell transplantation
KW - Prevention
KW - Review
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85059228103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059228103&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2018.11.033
DO - 10.1016/j.bbmt.2018.11.033
M3 - Review article
C2 - 30521975
AN - SCOPUS:85059228103
SN - 1083-8791
VL - 25
SP - e145-e154
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 5
ER -